Jan L. De Bleecker

Prof. Dr. Jan L. De Bleecker

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in The Lancet Neurology
Verified
Journal Article
Closed access
IGIlse Gijselinck
Ilse Gijselinck
TLTim Van Langenhove
Tim Van Langenhove
JZJulie van der Zee
Julie van der Zee
KSKristel Sleegers
Kristel Sleegers
SPStéphanie Philtjens
Stéphanie Philtjens
CBChristine Van Broeckhoven
Christine Van Broeckhoven

1 August 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SRSimon Rothwell
Simon Rothwell
RCRobert G Cooper
Robert G Cooper
ILIngrid E Lundberg
Ingrid E Lundberg
FMFrederick W Miller
Frederick W Miller
PGPeter K Gregersen
Peter K Gregersen
JLJanine Lamb
Janine Lamb
Objectives The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and extramuscular manifestations such as skin rashes and interstitial lung disease. We genotyped 2566 IIM cases of Caucasian descent using the Immunochip; a custom array covering 186 established autoimmune susceptibility loci. The cohort was predominantly comprised of patients with dermatomyositis (DM, n=879), juvenile DM (JDM, n=481), polymyositis (PM, n=931) and inclusion body myositis (n=252) collected from 14 countries through the Myositis Genetics Consortium. Results The human leucocyte antigen (HLA) and PTPN22 regions reached genome-wide significance (p<5×10−8). Nine regions were associated at a significance level of p<2.25×10−5, including UBE2L3, CD28 and TRAF6, with evidence of independent effects within STAT4. Analysis of clinical subgroups revealed distinct differences between PM, and DM and JDM. PTPN22 was associated at genome-wide significance with PM, but not DM and JDM, suggesting this effect is driven by PM. Additional suggestive associations including IL18R1 and RGS1 in PM and GSDMB in DM were identified. HLA imputation confirmed that alleles HLA-DRB1*03:01 and HLA-B*08:01 of the 8.1 ancestral haplotype (8.1AH) are most strongly associated with IIM, and provides evidence that amino acids within the HLA, such as HLA-DQB1 position 57 in DM, may explain part of the risk in this locus. Associations with alleles outside the 8.1AH reveal differences between PM, DM and JDM. Conclusions This work represents the largest IIM genetic study to date, reveals new insights into the genetic architecture of these rare diseases and suggests different predominating pathophysiology in different clinical subgroups.

15 December 2015 in Neurology
Verified
Journal Article
Open access
PDF file
IGIlse Gijselinck
Ilse Gijselinck
SMSara Van Mossevelde
Sara Van Mossevelde
JZJulie van der Zee
Julie van der Zee
ASAnne Sieben
Anne Sieben
SPStéphanie Philtjens
Stéphanie Philtjens
ESEric Salmon
Eric Salmon
Objective: To assess the genetic contribution of TBK1, a gene implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and FTD-ALS, in Belgian FTD and ALS patient cohorts containing a significant part of genetically unresolved patients. Methods: We sequenced TBK1 in a hospital-based cohort of 482 unrelated patients with FTD and FTD-ALS and 147 patients with ALS and an extended Belgian FTD-ALS family DR158. We followed up mutation carriers by segregation studies, transcript and protein expression analysis, and immunohistochemistry. Results: We identified 11 patients carrying a loss-of-function (LOF) mutation resulting in an overall mutation frequency of 1.7% (11/629), 1.1% in patients with FTD (5/460), 3.4% in patients with ALS (5/147), and 4.5% in patients with FTD-ALS (1/22). We found 1 LOF mutation, p.Glu643del, in 6 unrelated patients segregating with disease in family DR158. Of 2 mutation carriers, brain and spinal cord was characterized by TDP-43-positive pathology. The LOF mutations including the p.Glu643del mutation led to loss of transcript or protein in blood and brain. Conclusions: TBK1 LOF mutations are the third most frequent cause of clinical FTD in the Belgian clinically based patient cohort, after C9orf72 and GRN, and the second most common cause of clinical ALS after C9orf72. These findings reinforce that FTD and ALS belong to the same disease continuum.

1 June 1999 in Neuromuscular Disorders
Verified
Journal Article
Closed access
JBJan L. De Bleecker
Jan L. De Bleecker
VMVeronique I Meire
Veronique I Meire
WDWim Declercq
Wim Declercq
EAElisabeth H Van Aken
Elisabeth H Van Aken

1 April 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MHMegan K Herbert
Megan K Herbert
JSJudith Stammen-Vogelzangs
Judith Stammen-Vogelzangs
MVMarcel M Verbeek
Marcel M Verbeek
ARAnke Rietveld
Anke Rietveld
ILIngrid E Lundberg
Ingrid E Lundberg
GPGer Pruijn
Ger Pruijn
Objectives The diagnosis of inclusion body myositis (IBM) can be challenging as it can be difficult to clinically distinguish from other forms of myositis, particularly polymyositis (PM). Recent studies have shown frequent presence of autoantibodies directed against cytosolic 5′-nucleotidase 1A (cN-1A) in patients with IBM. We therefore, examined the autoantigenicity and disease specificity of major epitopes of cN-1A in patients with sporadic IBM compared with healthy and disease controls. Methods Serum samples obtained from patients with IBM (n=238), PM and dermatomyositis (DM) (n=185), other autoimmune diseases (n=246), other neuromuscular diseases (n=93) and healthy controls (n=35) were analysed for the presence of autoantibodies using immunodominant cN-1A peptide ELISAs. Results Autoantibodies directed against major epitopes of cN-1A were frequent in patients with IBM (37%) but not in PM, DM or non-autoimmune neuromuscular diseases (<5%). Anti-cN-1A reactivity was also observed in some other autoimmune diseases, particularly Sjögren's syndrome (SjS; 36%) and systemic lupus erythematosus (SLE; 20%). Conclusions In summary, we found frequent anti-cN-1A autoantibodies in sera from patients with IBM. Heterogeneity in reactivity with the three immunodominant epitopes indicates that serological assays should not be limited to a distinct epitope region. The similar reactivities observed for SjS and SLE demonstrate the need to further investigate whether distinct IBM-specific epitopes exist.

5 November 2013 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
Boel De PaepeBoel De Paepe
Boel De Paepe
JBJan L. De Bleecker
Jan L. De Bleecker
Duchenne muscular dystrophy is a severe inherited muscle disease that affects 1 in 3500 boys worldwide. Infiltration of skeletal muscle by inflammatory cells is an important facet of disease pathophysiology and is strongly associated with disease severity in the individual patient. In the chronic inflammation that characterizes Duchenne muscle, cytokines and chemokines are considered essential activators and recruiters of inflammatory cells. In addition, they provide potential beneficiary effects on muscle fiber damage control and tissue regeneration. In this review, current knowledge of cytokine and chemokine expression in Duchenne muscular dystrophy and its relevant animal disease models is listed, and implications for future therapeutic avenues are discussed.